written on 19.03.2014
Tags:
,

Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use

TAGS: ,

Astellas and Medivation today said they are asking the FDA for approval for Xtandi to be used on patients with metastatic castration-resistant prostate cancer who have not received chemotherapy.

Latest Report